This trial is evaluating whether FT516 will improve 2 primary outcomes and 5 secondary outcomes in patients with Acute Myeloid Leukemia (AML). Measurement will happen over the course of Day 29.
This trial requires 234 total participants across 4 different treatment groups
This trial involves 4 different treatments. FT516 is the primary treatment being studied. Participants will be divided into 4 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
"This estimate is for all AML, CML, and PLL. It does not estimate ALL and CLL separately. The age-adjusted AML risk [the number of new cases per million people aged 15 and older in a given year] is 1.6 (95% confidence interval (1.5-1.7)) and varies with age, gender and race.\n" - Anonymous Online Contributor
"Signs of acute leukemia include fever, fatigue, and a decreased appetite. Other symptoms of leukemia may be present, such as diarrhea or constipation, itching, a feeling of general malaise, or a skin rash. Chronic leukemias present as chronic unexplained fever without other specific symptoms. It may also be possible to see these signs on the skin before other symptoms appear." - Anonymous Online Contributor
"A combination of genetic, environmental and random chance factors are mostly responsible for leukemia. Hereditary disorders (not specifically acute leukemia or leukemia) are usually not the main cause of leukaemia. Those conditions with other genetic syndromes may be the trigger for the development of the disease. Those with chronic leukaemia usually also have other conditions that contribute to their disease. These secondary conditions can be very serious and are likely to be one of the principal reasons why the patient ends up hospitalized or dies. It is impossible to know for sure all of the factors that contribute to leukemia." - Anonymous Online Contributor
"A cancer causing a large number of white blood cells. In general it describes a symptom or a lab parameter. 'Leukemia' specifically refers to a type of cancer cell type. There are several leukemias involving specific cell types such as AML, B lymphoma, and T lymphoma among others." - Anonymous Online Contributor
"Many of the treatments that are currently utilized are also used in the treatment of the most common type of cancer, leukemia. This leads to a need for treatment guidelines in the area of leukemia." - Anonymous Online Contributor
"Chronic myeloid leukemias may respond to chemotherapy but the response is partial. Early stage acute lymphocytic leukemias respond well to induction chemotherapy with a 50% 5-year survival. The response to maintenance or consolidation chemotherapy is unpredictable. The response rate to induction chemotherapy may vary from 3% to 85% depending on the clinical sub-type of the disease at time of diagnosis. The majority of acute lymphocytic leukemias have a dismal prognosis. Chronic or acute myeloid leukemias have not yet been cured and have a mean survival time of 4-5 months." - Anonymous Online Contributor
"Patients with acute myeloid leukemia who are not interested in immediate disease-free survival benefit most from clinical trial participation. People with CML may not find clinical trial participation justified depending on their anticipated survival time. If a clinical trial would improve chances of survivorship in patients who seem to be candidates, they should consider it." - Anonymous Online Contributor
"This report describes two important new aspects of ft516: a novel mechanism of action, and selective inhibition of the protein kinase B2, or Akt. These data are consistent with the hypothesis that the efficacy of ft516 is mediated by its ability to inhibit PI3K/Akt/mTOR signalling. Pharmacological validation of ft516 inhibition of this signalling pathway is essential for further refinement, but we expect that the combination of these two features will yield a clinically useful inhibitor." - Anonymous Online Contributor
"Results from a recent clinical trial show that treatment with ft516 dramatically improves survival and slows progression in mice bearing human B-cell leukemia xenografts. Specifically, treatment with ft516 significantly increased the number of mice that remain in remission as well as the time to tumor relapse, providing support for the idea that ft516 may be an effective treatment for B-cell disease." - Anonymous Online Contributor
"The average age of diagnosis of leukemia in children (≤ 19 years) is 10.5 years compared to that of lymphoematosis (≤ 17.4 years). The age-adjusted incidence of ALL peaked around 10 years in this study and has declined slightly beyond it; the peak of incidence in children (≤ 19 years) was between 1990 and 1995. The decline was also seen in childhood ALL and childhood T-ALL. As childhood ALL started in 1991, this might have some impact on future risk estimation/prediction. Childhood ALL incidence was around 4.4 and 2.5 for boys and girls, respectively. Although our research did not mention it, the childhood ALL incidence in the 1990s was less than 10." - Anonymous Online Contributor
"ft516 demonstrated efficacy for the treatment of patients with chronic leukemia, and the results of this study may help to guide further studies of ft516 in chronic-phase patients." - Anonymous Online Contributor
"Survival of patients with CLL (chronic lymphocytic leukemia) depends upon the type of disease present, the age of the patient, and the characteristics of the individual patient. Survival varies not only between those who have the disease for a year or two vs. those who have the disease for 10 or 20 yr, but also within each category according to each specific cancer." - Anonymous Online Contributor